Tizanidine Tablet
Product Images NDC 70771-1335

6 FDA label images from Zydus Lifesciences Limited · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine (NDC 70771-1335). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Zydus Lifesciences Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 01)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 01)
Chemical structure of tizanidine hydrochloride, showing its molecular framework including a chlorinated aromatic ring and a thiazole ring with attached nitrogen-containing groups.*
FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 02)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 02)
A pharmacokinetic line graph showing plasma tizanidine concentration (ng/mL) over 24 hours from dosing. The graph compares 4 mg tizanidine tablets and capsules taken with or without food, illustrating variations in drug concentration over time for each condition.*
FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 03)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 03)
A line graph showing improvement in Ashworth Score over time post-dose in hours for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth Score, with negative values indicating more improvement. The x-axis spans 0 to 6 hours post-dose, illustrating the changes and differences between the three groups over time.*
FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 04)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 04)
A line chart showing improvement in Ashworth Score for tizanidine (mean dose 28.8 mg) versus placebo at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). Tizanidine data points show greater improvement with error bars, while placebo points show minimal to no improvement.*
FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 05)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 05)
Label for Tizanidine Tablets, USP 2 mg oral tablets by Zydus Lifesciences Limited. The label states the product contains 150 tablets per container, is Rx only, and includes a warning that these tablets are not interchangeable with Tizanidine Capsules. Storage and dispensing instructions are provided along with manufacturer details from Ahmedabad, India.*
FDA Label Image

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 06)

Figure (74aceb7a 4290 4ed2 9136 07b27fff9cd9 06)
Label for tizanidine tablets USP 4 mg by Zydus Lifesciences Limited. The label shows the NDC 70771-1336-8 and states the package contains 150 tablets for prescription use only. It includes warnings about child resistance, storage at controlled room temperature, and a caution that tablets are not interchangeable with tizanidine capsules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.